Inhaled corticosteroids in COPD: the clinical evidence

Pierre Ernst¹,², Nathalie Saad¹ and Samy Suissa²,³

Affiliations: ¹Dept of Medicine, Pulmonary Division, Jewish General Hospital, Montreal, Canada. ²Centre for Clinical Epidemiology, Lady Davis Research Institute, Jewish General Hospital, Montreal, Canada. ³Dept of Epidemiology and Biostatistics, McGill University, Montréal, Canada.

Correspondence: Pierre Ernst, Centre for Clinical Epidemiology, Lady Davis Research Institute, Jewish General Hospital, 3755 Cote Ste-Catherine, Montreal, Quebec, H3T 1E2, Canada. E-mail: pierre.ernst@mcgill.ca

ABSTRACT In this article, we focus on the scientific evidence from randomised trials supporting treatment with inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD), including treatment with combinations of long-acting β-agonist (LABA) bronchodilators and ICS. Our emphasis is on the methodological strengths and limitations that guide the conclusions that may be drawn.

The evidence of benefit of ICS and, therefore, of the LABA/ICS combinations in COPD is limited by major methodological problems. From the data reviewed herein, we conclude that there is no survival benefit independent of the effect of long-acting bronchodilation and no effect on FEV₁ decline, and that the possible benefit on reducing severe exacerbations is unclear. Our interpretation of the data is that there are substantial adverse effects from the use of ICS in patients with COPD, most notably severe pneumonia resulting in excess deaths.

Currently, the most reliable predictor of response to ICS in COPD is the presence of eosinophilic inflammation in the sputum. There is an urgent need for better markers of benefit and risk that can be tested in randomised trials for use in routine specialist practice. Given the overall safety and effectiveness of long-acting bronchodilators in subjects without an asthma component to their COPD, we believe use of such agents without an associated ICS should be favoured.

The benefits of ICS in COPD are limited. Better tools are needed to identify which patients might benefit. http://ow.ly/EwuhS
Introduction
Chronic obstructive pulmonary disease (COPD) has become a major worldwide killer [1] as well as causing very substantial morbidity and costs [2–4]. In most places in the world, COPD results from cigarette smoking and, therefore, the prevention of smoking [5] and the treatment of nicotine addiction should be the first priority in tackling COPD. However, far greater amounts of money are spent on drug therapy for COPD than on smoking cessation. In this narrative review, we will focus on the scientific evidence supporting treatment with inhaled corticosteroids (ICS) in COPD, including treatment with combinations of long acting β-agonist bronchodilators (LABA) and ICS. This scientific evidence includes observational studies that have generally shown very favourable outcomes of ICS and LABA/ICS on major COPD outcomes such as hospitalisation and mortality [6–9]. We have argued that these studies are affected by time-related biases that exaggerate the benefit of ICS [10, 11]. In this article, we will mostly restrict our review to randomised trials of ICS and LABA/ICS. Our emphasis will be on the methodological strengths and limitations that guide the conclusions that may be drawn as to the efficacy and safety of ICS and LABA/ICS in the treatment of COPD (table 1).

Early randomised clinical trials of ICS alone
The early trials of ICS therapy in COPD were carried out in patients with mild disease, with a baseline forced expiratory volume in 1 s (FEV1) near 80% predicted [12, 13]. Neither of these studies was able to show a benefit on decline in FEV1 and in the study by Vestbo et al. [13], the exacerbation rate was similar in the ICS and placebo groups. The Lung Health Study included patients with a lower FEV1 (mean 56% predicted) and found no difference in decline in lung function in those randomised to the ICS triamcinolone (fig. 1), while the ICS-treated group reported fewer visits to a physician for respiratory illness [14]. Subsequent trials included patients with more severe airflow obstruction (mean FEV1 ≤ 50% predicted) and reported decreased rates of exacerbation or prolonged time to first exacerbation [15–18] with ICS. A meta-analysis of these studies concluded that there was an overall 30% reduction in acute exacerbations of COPD (AECOPD) with ICS [19]. We have criticised the analysis of exacerbations in these early studies, however [20, 21]. Principally, some of these studies did not weight the rate of exacerbations according to differences in duration of follow-up between patients, which will exaggerate the influence of those subjects dropping out early. This is especially problematic in COPD studies with long durations of follow-up where dropout rates have been in the range of 20–50% and observed to occur early after randomisation, more so in the placebo group. Authors further assumed that patients were homogeneous as to their rates of AECOPD rather than accounting for the fact that some patients may have many exacerbations and many patients none [22]. This assumption underestimates the variation in the data and will provide falsely low p-values and narrow confidence intervals [20, 21]. Therefore, these early studies suggesting a benefit of ICS in reducing exacerbations among COPD patients with severe airways obstruction are likely to have overestimated the potential benefit. More recent studies of ICS/LABA [23, 24] have used weighting of exacerbations according to total person-time of follow-up. In addition, the more current studies now consider the wide between-patient heterogeneity in exacerbation rates using the appropriate statistical techniques. Whether using an overdispersion parameter in the Poisson regression analysis of the rates [21] or the practically equivalent approach of a negative binomial analysis [24–26], this important variability in the analysis of COPD trials involving exacerbations is now well recognised [27]. While ICS probably do reduce moderate exacerbations of COPD [28], ICS alone are not superior to LABA and are less safe according to a Cochrane meta-analysis by Spencer et al. [29] that pooled randomised controlled trial (RCT) data comparing the benefits of ICS to LABA, each used singly.

TABLE 1 Limitations of the evidence suggesting that inhaled corticosteroids (ICS) and long-acting β-agonists (LABA)/ICS decrease exacerbations of chronic obstructive pulmonary disease

<table>
<thead>
<tr>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Most trials do not follow patients for the outcome of exacerbations after drug discontinuation (not ITT)</td>
</tr>
<tr>
<td>Loss to follow-up frequent and related to both treatment received and outcome, causing bias</td>
</tr>
<tr>
<td>Exacerbations variably defined</td>
</tr>
<tr>
<td>Differences between groups possibly exaggerated by withdrawal of ICS in placebo and LABA groups</td>
</tr>
<tr>
<td>Incorrect calculation of NNT</td>
</tr>
<tr>
<td>Incorrect adjustment for heterogeneity of number of exacerbations between patients in early studies</td>
</tr>
</tbody>
</table>

ITT: intention to treat; NNT: number needed to treat.
RCTs of LABA/ICS combinations and their methodological limitations
Towards a Revolution in COPD Health (TORCH) [25] was a landmark study in many ways. It recruited a sufficient number of patients followed for 3 years to examine mortality in relation to treatment of COPD with ICS and the LABA/ICS combination. For the outcome of all-cause mortality, the study provided a true intention-to-treat (ITT) analysis, having followed all patients to the end of the 3-year study period for the death end-point, regardless of whether they had continued the study medications. The study conclusively showed that ICS do not reduce mortality in patients with COPD. There was a trend toward improved survival with the LABA/ICS compared with placebo, but this did not achieve statistical significance. There were four treatment groups in TORCH: placebo, fluticasone, salmeterol, and salmeterol and fluticasone combined in a single inhaler. This factorial design allows one to derive information on the individual effects of salmeterol and fluticasone, not only from those subjects randomised to the individual agent but also from those receiving the combination. Such a factorial analysis, performed post hoc, found a statistically significant and important 19% (95% CI 6–30%) survival advantage with the use of the LABA salmeterol but none whatsoever from the fluticasone component [30].

Unfortunately, a true ITT analysis was not possible for symptoms, exacerbations, FEV1 decline and quality of life because follow-up of these outcomes was not obtained after the subjects discontinued the study medications. For these outcomes, TORCH becomes a prospective cohort study where bias in the estimate of the effect will result if the likelihood of dropping out differs according to the treatment received at randomisation and is related to the outcome under study. For example, a subject who feels unwell in relation to early signs of exacerbation may withdraw from the study and the subsequent severe exacerbation would not be counted. This is well illustrated by the ~25% rate of severe exacerbation in COPD subjects ≥31 days after discontinuing randomised therapy [31]. Such a bias would probably not be significant if the rate of discontinuation was low. In TORCH, however, 35% of subjects randomised to LABA/ICS and 45% of those randomised to the placebo group did not complete the 3-year follow-up, including the 21% who dropped out in the first year. Furthermore, loss to follow-up was not random: patients who dropped out were older, had a lower FEV1 and greater exacerbation history [32].

It has been argued that the higher dropout rate in the placebo group and the availability of the study medications on the market will have led to an underestimation of the treatment benefit [31, 32]. This is not necessarily so. The one study that did follow patients to the end of the study period was unable to show a reduction of exacerbations with the addition of LABA/ICS to tiotropium [33]. Using data from this same study, Aaron et al. [20] were able to demonstrate an important exaggeration of the reduction in risk of exacerbation by simulating dropping patients who stopped the study medications. Furthermore, many subjects recruited to TORCH were receiving the treatments under study at the time of recruitment and were required to stop these prior to randomisation. This may be only a minor problem for addressing benefits of long-acting bronchodilators, as subjects were allowed to use short-acting bronchodilators. For ICS, however, one might speculate that subjects who were previously on ICS would tend to be those who had experienced the most benefit (as they might be expected to be more compliant to this therapy) and, therefore, the salmeterol and placebo group experience may reflect, at least in part, the withdrawal of ICS. This is supported by subsequent analyses of TORCH that showed that having ICS withdrawn at recruitment was a predictor of withdrawal from the study [32]. Again, using information gathered during the Canadian...
Optimal Therapy of COPD Trial, we were able to show that the reduction in exacerbations with the ICS component of the LABA/ICS arm was limited to subjects who were already receiving ICS at the time of study initiation and were possibly more likely to have experienced benefit [34]. A subsequent re-analysis of TOCCH did not find a difference in exacerbation rates according to prior ICS use, however [35].

Cardiovascular disease is common in patients with COPD and contributes substantially to mortality [36–38]. Observational studies have suggested possible benefits of ICS on cardiovascular outcomes [39, 40]. A post hoc analysis of cardiovascular events in the TOCCH study suggested that the LABA/ICS combination may be cardioprotective [41]. SUMMIT (the Study to Understand Mortality and Morbidity in COPD) will examine the potential benefits of the new LABA/ICS combination, vilanterol/fluticasone furoate, on survival among patients with moderate COPD and cardiovascular comorbidity [42]. Unfortunately, patients already on a LABA/ICS combination or its components will be recruited and their medications stopped. Therefore, once again, the observed effects will be those resulting from a combination of direct treatment effects and withdrawal of prior treatments, making the results of that trial difficult to interpret [43].

The most clinically pertinent comparison to delineate the role of ICS in COPD is the contrast of LABA/ICS with bronchodilators alone. A recent meta-analysis of studies comparing LABA/ICS to LABA alone questioned the superiority of the combination in reducing exacerbations, noting that no reduction in COPD hospitalisations was seen and voiced concerns as to the analysis and the availability of data [44]. Specifically, attrition rates were high and the analysis of exacerbations remains problematic [20]. A recent study of a new LABA/ICS combination at various doses versus the LABA alone also did not find a benefit of the LABA/ICS combination versus the LABA alone on severe exacerbations [24, 45].

In several articles reporting a reduction in AECOPD with a LABA/ICS combination, authors have provided a number needed to treat (NNT) that appears very favourable [23–25]. The NNT is based on the absolute risk difference (one divided by the absolute difference in the proportion of subjects with the outcome event). This proportion is measured by the cumulative incidence of the event over the treatment period, using statistical tools such as the Kaplan–Meier curve, which applies both for a dichotomous outcome such as death and, if the outcome can occur more than once, the time to the first occurrence (e.g. the first AECOPD). A study by KARDO et al. [23] reported a NNT of 3 subjects to prevent one AECOPD, while the number reported in TOCCH was 4 and was 3.3 in a recent study of a new LABA/ICS [24, 25]. This was obtained by calculating an absolute risk reduction based not on the difference in the proportion of subjects with an AECOPD, but rather on differences in rates of AECOPD in two groups, and termed an “event-based” NNT [46]. This use of the rate rather than the cumulative incidence is inappropriate and illogical, as demonstrated by AARON and FERGUSON [47]. Suissa has described an alternative method for the correct calculation of the number to treat in this context when the Kaplan–Meier curve of the cumulative incidence is not available using a trial of fluticasone-salmeterol versus salmeterol alone [48, 49]. Suissa found an event-based NNT of 14 rather than the NNT of 2 reported in the paper.

The seminal work of FLETCHER and PETO [50] demonstrated the progressive and excessive decline in FEV1 to be a major feature of COPD. Therefore, reducing FEV1 decline has been a goal of many large COPD treatment trials. As mentioned previously, early trials of ICS in patients with mild COPD did not show a slowing of the decline in FEV1 [12, 13]. Two meta-analyses including studies with a broader range of patients came to opposite conclusions based on an aggregate analysis of mostly the same studies [51, 52]. A Cochrane review in 2012 [28] concluded that ICS in COPD did not modify FEV1 decline. The TOCCH study examined the effect of an LABA/ICS combination, as well as the individual components, on FEV1 decline [53]. The authors reported that all treatment groups showed significantly less decline in FEV1 than the placebo group and further stated that the difference in decline compared with placebo was minimised due to the greater dropout rate in the placebo group. This is a misconception, as previously demonstrated by one of us [54]. In the analysis of FEV1 decline in the TOCCH data, nearly 18% of patients in the placebo group did not have an FEV1 measurement at 6 months, the time from which decline was measured [53]. There were also fewer patients in the placebo group who had the full complement of follow-up measurements. These missing results did not occur at random and exaggerate differences in FEV1 decline between the placebo and treatment groups through the statistical phenomenon of regression to the mean [54]. This is a further consequence of not following patients until the end of the study period and particularly after treatment discontinuation, thus not permitting a true ITT analysis.

Safety of ICS and LABA/ICS in COPD
COPD patients are at greater risk of pneumonia [55] and are at increased risk of dying when contracting pneumonia [56]. The TOCCH study was the first to report an excess of pneumonia among COPD patients receiving ICS either alone or in combination with a LABA. The significance of this finding was not immediately accepted because pneumonia was not a pre-specified outcome and chest-radiographic confirmation of the diagnosis was not required [57]. Our group carried out a large prospective cohort
study in a healthcare administrative database and found an overall 70% (rate ratio (RR) 1.70, 95% CI 1.63–1.77) increase in pneumonia requiring hospitalisation, with the greatest risk (RR 2.25, 95% CI 2.07–2.44) seen in patients dispensed a daily fluticasone-equivalent dose ≥1000 µg [58], the dose used in TORCH and other large COPD trials [25, 33, 59]. Subsequent meta-analyses of randomised trials again confirmed the excess pneumonia risk [60, 61]. In TORCH, the risk of pneumonia was greatest in patients with an FEV1 <50% predicted and those with a prior COPD exacerbation [57], exactly the group where a LABA/ICS combination is recommended. An excess of pneumonia was also observed in the Investigating New Standards for Prophylaxis in Reduction of Exacerbations (INSPIRE) study comparing salmeterol/fluticasone to tiotropium [59]. The excess was observed for pneumonias associated with a current or recent exacerbation [62], which appears paradoxical, given the reported reduction in exacerbations with LABA/ICS combinations. A recent large Canadian observational study did not find an excess of pneumonia in subjects initiating treatment with a LABA/ICS combination compared with a LABA alone [63]. The study design used an ITT approach where ICS use was measured only at cohort entry. With pneumonias possibly occurring up to 5 years later, ICS exposure needed to be updated over time, but was not. Patients classified as users of ICS at cohort entry were exposed to ICS for only 47% of the days in the first year and 34% subsequently, while patients classified as nonusers of ICS were actually exposed to ICS for 6% of the days in the first year, increasing to 23% by year 5. Such misclassification of exposure will necessarily attenuate high risks towards the null.

In both the TORCH and INSPIRE studies, there were a relatively small number of pneumonias compared with COPD exacerbations. Using the relative frequencies of events to examine drug effects can be misleading; the results of these studies have been misinterpreted, as demonstrating that a reduction in frequent exacerbations due to the LABA/ICS combination must be more important than an excess of infrequent pneumonias. A way of dealing with these issues is to use comparative effect measures such as the NNT. One of us has shown that the NNT for pneumonias and that for a reduction in COPD exacerbations are quite similar [49]. For example, in the TORCH study, 44 subjects must be treated for 3 years to prevent one patient from having an exacerbation while 16 subjects treated over the same time period will result in one excess case of pneumonia [49]. The excess in pneumonia with the LABA/ICS combination has also been observed with lower doses of the fluticasone component of the LABA/ICS combination [26, 48].

Surprisingly, a meta-analysis of randomised trials of budesonide in COPD, either singly or as part of a LABA/ICS combination, did not find an excess risk of pneumonia [64]. Two observational studies also found a lower risk of severe pneumonia with budesonide compared with fluticasone [65, 66]. There is the possibility, however, that in both jurisdictions in which these studies were carried out, use of the formoterol/budesonide combination may have been a marker of asthma where ICS are not associated with an excess in pneumonia [67]. While the authors of both these studies attempted to limit their analyses to patients with COPD, this may not have been entirely successful. However, a recent study of a new LABA/ICS combination containing fluticasone furoate found an excess of eight pneumonia deaths, seven in the group receiving the higher-than-recommended dose of this agent, suggesting that fluticasone itself may be particularly troublesome [24]. However, a recent meta-analysis did not exonerate budesonide [68].

Once hospitalised, COPD patients with pneumonia who were receiving ICS are at no greater risk of mortality subsequently [58, 69, 70]. This has been misinterpreted as an absence of an excess in pneumonia deaths among COPD patients on ICS [57, 71]. Since a greater number of COPD patients receiving ICS are hospitalised for severe pneumonia, more will die from pneumonia even if the case fatality rate is the same once hospitalised. This is emphasised in our results in a large database study of nearly 24,000 pneumonias in which patients receiving high doses of ICS equivalent to ≥1000 µg fluticasone propionate had a 70% greater risk of pneumonia hospitalisation resulting in death within 30 days [58] as well as the recent study of vilanterol/fluticasone furoate where eight deaths from pneumonia occurred in those receiving fluticasone furoate [24].

Pneumonia is the most troublesome adverse effect of ICS in patients with COPD given the size of the relative increase in risk, the frequency of the event and the associated excess mortality. Current use of ICS is also associated with an increase in the risk of active tuberculosis in a low-prevalence setting (RR 1.33, 95% CI 1.04–1.71), although there is no added risk in patients who already experience an increase in risk from having received oral corticosteroids in the prior year [72]. A similar increase in the risk of tuberculosis was observed in an area with higher prevalence (RR 1.20, 95% CI 1.08–1.34), again limited to subjects without concomitant use of oral corticosteroids [73]. COPD is also a risk factor for infection with nontuberculous mycobacteria and there is a further dose-related increased risk with ICS [74]. Interestingly, as was the case with pneumonia, the risk appeared to be greater for fluticasone than for budesonide [74]. In a recent study, we did not find an increase in the risk of herpes zoster infections with ICS [75].
Corticosteroids affect bone metabolism and increase the risk of osteoporosis [76]. Airflow obstruction, especially if severe, is a further risk for osteoporosis [77]. ICS use is associated with a small additional increase in risk of fractures and the risk increases by approximately 6–12% at high daily doses of ICS [78–81].

ICS have been shown to have adverse metabolic effects. Early database studies did not identify an increased risk of diabetes in users of ICS [82, 83]. These studies examined a period of time when the predominant ICS was low-dose beclomethasone. The incidence of diabetes in patients with COPD is insufficiently common for an increase in risk to be picked up in the large COPD trials. A recent meta-analysis of trials of budesonide in both asthma and COPD did not find an excess of diabetes reported as an adverse outcome [84]. However, an increase in blood glucose has been described among diabetic patients receiving ICS [85]. Furthermore, in a crossover study, inhaled fluticasone was shown to increase glycosylated haemoglobin [86]. Recently, in a large database study including patients with both asthma and COPD, we found a 34% relative increase in the risk of new-onset diabetes (RR 1.34, 95% CI 1.29–1.39) with current use of ICS, with a higher risk with daily doses equivalent to fluticasone ≥1000 µg (RR 1.64, 95% CI 1.52–1.76) [87]. There was also a 34% increase in the risk of progressing to insulin dependence among diabetics treated with oral hypoglycaemic agents [87].

Concerns regarding the occurrence of adrenal insufficiency with ICS were first raised in children, particularly in relation to fluticasone [88–90], as well as in in HIV patients treated with ritonavir which severely affects the metabolism of ICS [91, 92]. Fluticasone may be associated with greater adrenal suppression than budesonide [93]. Mortimer et al. [94] carried out a nested case–control analysis of a cohort of patients followed by general practitioners in the UK and found a small increase in the risk of adrenal insufficiency that was largely explained by a history of use of oral corticosteroids. There was a suggestion of an independent risk with higher doses of ICS and for fluticasone. In a larger study in the Quebec health administrative databases, we again found a large excess risk of adrenal insufficiency related to the cumulative dose of oral corticosteroids, but again a suggestion of a significant independent risk with daily doses of ICS equivalent to fluticasone ≥1000 µg (RR 1.84, 95% CI 1.16–2.90) [95]. Interestingly, the risk of adrenal insufficiency with ICS was more pronounced in patients with COPD than in patients with asthma [95]. Newer ICS have contrasting effects on adrenal function, with ciclesonide being less suppressive than fluticasone [96], while mometasone and fluticasone appear equivalent [97].

Cumming et al. [98] demonstrated the association between reported use of ICS assessed by questionnaire and the risk of cataracts detected by screening. The need for cataract extraction in the elderly was subsequently linked to prolonged use of ICS (≥3 years or more) (odds ratio 3.06, 95% CI 1.53–6.13) in a health administrative database, with a more pronounced risk at daily doses of budesonide or beclomethasone of >1 mg [99]. A lower risk was found in a general practice prescription database with the risk restricted to those >40 years of age [100]. The risk may have been attenuated, however, as exposure to ICS was based on prescriptions rather than on drugs dispensed to patients. We were able to demonstrate an excess of cataracts, including severe cataracts requiring extraction, even at relatively low doses of ICS equivalent to daily doses of beclomethasone ≤500 µg [101].

While oral corticosteroids increase intraocular pressure and the risk of a diagnosis of glaucoma [102], it is far less clear whether ICS actually increase the risk of open-angle glaucoma requiring treatment. In an administrative database study, Garbe et al. [103] reported no overall increase in risk of glaucoma or increased intraocular pressure with current use of ICS, but a small increase in risk at higher doses used for ≥3 months. However, treatment for ocular hypertension was only required in approximately half of the cases. In a subsequent study, limited to cases of open-angle glaucoma requiring treatment, we did not find an increase in risk with current use of ICS, even at higher doses [104].

**COPD phenotypes or how to predict which patients benefit from ICS**

Personalised medicine has not come to COPD. Part of the problem lies in the difficulty in distinguishing asthma from COPD in patients with persistent airflow limitation. Guidelines have recognised that COPD and asthma may co-exist [105, 106] if patients with asthma smoke and airway hyperresponsiveness has been shown to predict decline in lung function over time in smokers with early COPD [107]. To muddy the waters further, the presence of fixed airways obstruction is not uncommon among nonsmokers [108, 109]. A proportion of these cases are probably untreated asthma, the result of airway remodelling in chronic asthma despite treatment or of severe childhood asthma [110, 111]. In the recent BOLD (Burden of Obstructive Lung Disease) initiative [112], the occurrence of post-bronchodilator airflow limitation found during screening of population-based samples has been termed COPD, regardless of potential aetiological factors such as smoking, asthma or childhood respiratory disease. As has been pointed out, such an approach, if adopted clinically, is unlikely to lead to the correct therapeutic decision for many patients [113] but, rather, has led to widespread confusion [114].
The recent Global Initiative for Asthma (GINA) guideline includes a new chapter on the asthma–COPD overlap syndrome (ACOS) developed in conjunction with the GOLD (Global Initiative for Chronic Obstructive Lung Disease) guideline group. It provides suggestions of clinical characteristics that might allow clinicians to identify an asthma component in patients labelled as having COPD [115]. Therapeutic responses in these patients have never really been studied, however, as asthma is an exclusion criterion in most therapeutic trials of COPD, while COPD is an exclusion criterion in trials of asthma. Nevertheless, it is proposed that if features of both asthma and COPD (see Box 5-4 in the GINA report [115]) are present, the term ACOS may be applied and treatment for asthma initiated. This approach has not been validated and is unlikely to be useful in differentiating patients with a significant degree of persistent airflow obstruction and daily symptoms, as both these characteristics are considered features of COPD. Identifying different clinical phenotypes for these patients is the key to providing individualised treatment that maximises benefit and reduces harm [116]. While current guidelines identify patients with frequent exacerbations as a clinical phenotype, such patients may rather be farther along in the natural history of the disease [117]. More importantly, while studies of LABA/ICS combinations aimed primarily at reducing exacerbations have recruited patients with prior exacerbations [23, 24, 26], this does not provide evidence that such patients benefit more from ICS.

The ACOS phenotype appears to provide the most confidence as to the benefit of including an ICS in the treatment regimen. A recent, large observational study reported a survival advantage among patients with COPD starting LABA/ICS versus LABA alone. This survival benefit was observed in those patients with a concomitant diagnosis of asthma but not in those without [63]. Various clinical characteristics might be used to better identify such patients. GINA has proposed that the early onset of airway disease, including a history of childhood asthma as well as a history of atopy, is suggestive of ACOS in patients with persistent airflow obstruction. Again according to GINA, laboratory features that point to an asthma component are a normal diffusing capacity and a large bronchodilator response (≥12% and 400 mL) [115]. Prior claims that bronchodilator response is not pertinent in the differential diagnosis of airflow obstruction are based on several arguments. First, bronchodilator response is not a stable feature in COPD [118], as is also the case with asthma. This does not lessen the fact that large bronchodilator responses (≥12% and 400 mL) are common in asthma, especially if insufficiently treated, and are uncommon in COPD [115, 118, 119]. A study by CALVERLEY et al. [119], which is frequently quoted to argue against the utility of bronchodilator response as a prognostic factor or predictor of treatment response, is based on an analysis of the ISOLDE (Inhaled Steroids in Obstructive Lung Disease in Europe) study in which the mean bronchodilator response to salbutamol was ~10% or 130 mL. This study had insufficient power to conclude as to the usefulness of larger bronchodilator responses. Similarly, in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) study, while 24% of patients with a diagnosis of COPD met the American Thoracic Society/European Respiratory Society reversibility criteria of an increase in FEV₁ of ≥12% and 200 mL, only 5% of patients met the reversibility criteria using a minimum volume increase of 400 mL. Therefore, the lack of prognostic and diagnostic significance of small responses to bronchodilator cannot be applied to larger responses. In the general population-based CanCOLD (Canadian Cohort of Obstructive Lung Disease) study, bronchodilator responsiveness was strongly associated with a physician diagnosis of asthma (table 2) [120].

Among patients with similar degrees of fixed airflow obstruction, the presence of sputum eosinophilia will distinguish those with asthma from those with COPD better than bronchodilator response or diffusing capacity [121]. In this study, however, the majority of the patients with asthma were nonsmokers. Sputum eosinophilia is a good predictor of response to corticosteroids in asthma and there is a suggestion that ICS response is limited to those with sputum eosinophilia [122, 123]. Sputum eosinophilia also seems to be common in smokers labelled as having COPD [124]. Several studies suggest that sputum eosinophilia in COPD patients also predicts response to corticosteroids [125, 126]. BRIGHTLING et al. [127] carried out a placebo-controlled crossover trial of the ICS mometasone, 800 µg daily for 6 weeks in patients with typical COPD (smokers, no response to bronchodilators on two occasions, no history of asthma and no exacerbation on withdrawal of prior ICS) and found that only subjects in the highest tertile of sputum eosinophilia improved their post-bronchodilator FEV₁ (fig. 2). However, sputum eosinophilia was not significantly reduced, as opposed to the reduction seen in their prior study using oral corticosteroids [125], suggesting that the dose and duration of ICS therapy may have been insufficient. In a sequential, single-blind study, LEIGH et al. [128] recruited patients with again, quite typical COPD, although bronchodilator response was not an exclusion criteria and 38% of patients had sputum eosinophilia. They found that the presence of sputum eosinophilia predicted response to ICS and ICS use was associated with a reduction in sputum eosinophils, although the reduction was significantly less marked than that observed with oral corticosteroids. In an RCT, a management algorithm for patients with COPD based on suppressing sputum eosinophilia to ≤3% was compared to usual specialist care. This strategy was able to reduce severe exacerbations requiring hospitalisation with, on average, no more ICS or oral corticosteroid
use than those in the usual-care group [129]. Surprisingly, in GLUCOLD (Groningen and Leiden Universities Study of Corticosteroids in Obstructive Lung Disease), the use of high-dose fluticasone in patients with COPD, over a 2.5-year period, was associated with an increase in sputum eosinophils [130]. Sputum inflammometry [131] has not been widely adopted, at least in part due to the technical expertise required [132]; however, it has been used successfully in routine specialist care by some [133]. While broader prospective studies including cost–benefit analyses would be helpful [134], sputum inflammometry currently appears to provide the single best measure to predict response to ICS among patients with significant airway disease [133]. It also provides information on the bacterial nature of exacerbations [135].

Other potential markers of response to ICS are needed. Peripheral blood eosinophils were found to predict eosinophilic exacerbations of COPD [135] and oral corticosteroid responsiveness of AECOPD [136]. Expired nitric oxide is of limited usefulness in COPD because it is affected by smoking and values fall with increasing airflow limitation [137, 138]. However, there may be some utility for expired nitric oxide in ACOS [139]. Airway hyperresponsiveness to methacholine or histamine may be a marker of phenotypic variability in COPD [140] but its measurement is confounded by the degree of airflow limitation at baseline and current smoking [141, 142]. Furthermore, it is not recommended in patients with severe airflow limitation [143].

A promising approach is to combine potential indicators of response to ICS into a predictive algorithm [144]. Cluster analysis has been applied to patients with signs of airway disease in the general population, providing phenotypes that may be more or less likely to respond to ICS [145]. This approach has been used in patients with a clinical diagnosis of COPD to define differences in comorbidity and prognosis, but potential markers of response to ICS were not included in the analysis [146]. An overlap syndrome of patients with severe COPD and markers of asthma has been identified using cluster analysis by some [145] but not others [147]. Simple allocation rules need to be developed and tested to provide a clinically useful tool [148] that can be applied to patients where the decision to treat or not with ICS is most pertinent; that is, patients with significant airway obstruction and a relevant smoking history (≥20 pack-years).

**TABLE 2 Indicators of a probable response to inhaled corticosteroids in patients with chronic obstructive pulmonary disease**

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>History of childhood asthma or atopy</td>
<td></td>
</tr>
<tr>
<td>Onset of respiratory disease prior to the age of 40 years</td>
<td></td>
</tr>
<tr>
<td>Cumulative smoking history &lt;20 pack-years</td>
<td></td>
</tr>
<tr>
<td>FEV1 bronchodilator response ≥12% and ≥400 mL</td>
<td></td>
</tr>
<tr>
<td>Normal diffusing capacity</td>
<td></td>
</tr>
<tr>
<td>Peripheral blood eosinophilia</td>
<td></td>
</tr>
<tr>
<td>Sputum eosinophilia</td>
<td></td>
</tr>
<tr>
<td>Not FEV1 &lt;50% predicted</td>
<td></td>
</tr>
<tr>
<td>Not history of frequent exacerbations</td>
<td></td>
</tr>
</tbody>
</table>

FEV1: forced expiratory volume in 1 s.
Conclusion
The evidence of benefit of ICS and, therefore, of the LABA/ICS combinations in COPD is limited by methodological problems. One must conclude that there is no survival benefit independent of the effect of long-acting bronchodilation and no effect on FEV1 decline, and that the possible benefit on reducing exacerbations is probably overestimated and, for severe exacerbations, not greater than that obtained with long-acting bronchodilators. However, there is substantial evidence for adverse effects from the use of ICS in patients with COPD, most notably severe pneumonia resulting in excess deaths. It therefore appears important to limit use of ICS to the minority of patients with COPD who might benefit. Currently, the most reliable predictor of response to ICS in COPD is the presence of eosinophilic inflammation in the sputum. There is an urgent need for more and better markers of benefit and risk that can be tested in randomised trials for use in routine specialist practice. It is time to start devising randomised trials for the future with methods that can incorporate these markers to optimise the treatment of highly heterogeneous COPD patients. Currently, given the overall safety and effectiveness of long-acting bronchodilators [149, 150] in subjects without an asthma component to their COPD, we believe use of such agents without an associated ICS should be favoured at all levels of COPD severity. A recent study of the gradual withdrawal of ICS in stable but severe patients with COPD was reassuring as to the safety of such an approach, finding no excess in moderate or severe exacerbations when compared to patients maintained on ICS [151] (fig. 3).

References
INHALED CORTICOSTEROIDS IN COPD | P. ERNST ET AL.


INHALED CORTICOSTEROIDS IN COPD | P. ERNST ET AL.


DOI: 10.1183/09031936.00128914

535


Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts.

Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression.


INHALED CORTICOSTEROIDS IN COPD | P. ERNST ET AL.